Qing Sarah Yuan - 27 Jul 2023 Form 4 Insider Report for Sigilon Therapeutics, Inc.

Role: CTOO
Signature: /s/ Matthew Kowalsky, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 27 Jul 2023
Net transactions value: +$55,488
Form type: 4
Filing time: 27 Jul 2023, 16:21:04 UTC
Previous filing: 01 Mar 2023
Next filing: 11 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SGTX	Common Stock	Options Exercise	$55,488	+2,884		$19.24^*	2,884	27 Jul 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SGTX	Stock Option (Right to Buy)	Options Exercise	$0	-2,884	-31%	$0.000000	6,346	27 Jul 2023	Common Stock	2,884	$19.24	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option vested as to 25% of the underlying shares of common stock on March 7, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
F2	Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.